Published in Oncogene on March 09, 2015
Mechanistic Effects of Calcitriol in Cancer Biology. Nutrients (2015) 0.82
Tumor suppressor maspin as a modulator of host immune response to cancer. Bosn J Basic Med Sci (2015) 0.75
Glossogyne tenuifolia (Hsiang-ju) extract suppresses T cell activation by inhibiting activation of c-Jun N-terminal kinase. Chin Med (2017) 0.75
Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects. Oncol Ther (2016) 0.75
Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy. Cancers (Basel) (2015) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov (2006) 14.01
Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol (1997) 11.57
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer (2006) 10.73
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med (1995) 8.31
Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature (1995) 7.52
Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene (2007) 7.13
Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science (1996) 6.02
Cyclosporine. N Engl J Med (1989) 5.67
Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell (1995) 5.64
Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res (2011) 5.30
Immune surveillance of tumors. J Clin Invest (2007) 5.04
Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer (2003) 4.99
Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2004) 4.20
HDAC family: What are the cancer relevant targets? Cancer Lett (2008) 4.17
Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol (2004) 3.95
Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature (1999) 3.93
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res (2000) 3.83
Toward an understanding of the molecular mechanisms of physiological cell death. Proc Natl Acad Sci U S A (1993) 3.80
New and emerging HDAC inhibitors for cancer treatment. J Clin Invest (2014) 3.35
Cyclosporin A inhibits activation-induced cell death in T-cell hybridomas and thymocytes. Nature (1989) 3.23
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol (2006) 3.12
T cell antigen receptor signal transduction pathways. Annu Rev Immunol (1996) 3.11
p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med (1998) 2.91
Activation-induced cell death in T cells. Immunol Rev (2003) 2.82
Escaping cell death: survival proteins in cancer. Exp Cell Res (1999) 2.73
Reactive oxygen species and programmed cell death. Trends Biochem Sci (1996) 2.68
Granzyme B is critical for T cell receptor-induced cell death of type 2 helper T cells. Immunity (2006) 2.21
Cyclosporine: five years' experience in cadaveric renal transplantation. N Engl J Med (1984) 2.10
HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity (2003) 2.10
Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death. J Neurosci (2005) 2.00
Sequential involvement of NFAT and Egr transcription factors in FasL regulation. Immunity (2000) 1.74
Expression and involvement of c-fos and c-jun protooncogenes in programmed cell death induced by growth factor deprivation in lymphoid cell lines. J Biol Chem (1992) 1.66
Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res (2006) 1.58
Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest (2006) 1.56
The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses. BMC Cancer (2003) 1.48
NF-κB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppression. J Biol Chem (2012) 1.24
Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle (2005) 1.22
Apoptosis signaling pathways and lymphocyte homeostasis. Cell Res (2007) 1.16
Differential expression of human histone deacetylase mRNAs in response to immune cell apoptosis induction by trichostatin A and butyrate. Biochem Biophys Res Commun (1998) 1.15
Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell (2002) 1.06
Protein kinase C regulates Fas (CD95/APO-1) expression. J Immunol (1998) 1.05
Activation-induced cell death in murine T cell hybridomas. Differential regulation of Fas (CD95) versus Fas ligand expression by cyclosporin A and FK506. Int Immunol (1996) 1.01
The critical role of protein kinase C-theta in Fas/Fas ligand-mediated apoptosis. J Immunol (2007) 0.96
Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood (2008) 0.95
A novel immunosuppressive drug, FTY720, prevents the cancer progression induced by cyclosporine. Cancer Lett (2002) 0.83